1 January 2011PatentsArchana Shanker

A revolution: biotech patents in India

In May 2011, Glenmark Pharmaceuticals entered into a licence agreement with Sanofi Aventis in one of the first-ever deals for a novel biologic molecule in India for the treatment of autoimmune diseases. Bharat Biotech, an Indian Biotech company, developed a diarrhoea vaccine to be supplied to the UN and other markets at $1 each, making it the cheapest vaccine available in the market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

India: Patents-in-waiting

23 September 2019 With pendency rates ranging up to four years, India’s patent owners have a range of options to protect their innovations while they wait, explains Joginder Singh of LexOrbis.

Jurisdiction reports

India jurisdiction report: Defending domain names

14 August 2020 With the rapid growth of the internet and globalisation, the marketing of products and services through websites and domain names has become a vital part of brand-building and commerce for trademark owners.

UPC docs 'excessively redacted' under GDPR claims transparency lawyer

L'Oréal sued over virtual makeup try-on simulator

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Q&A: EagleView counsel maps out route to IPR victory

WIPO in Saudi Arabia to finalise design law treaty

Douwe Egberts enjoys double shot over Nestlé in coffee patent rivalry

Startup CFO’s betrayal is a lesson in preparing for the worst

President Trump 2.0: Five major areas to watch

A revolution: biotech patents in India

More on this story

Editor's picks

Editor's picks

More articles